Severe withdrawal from short-term transdermal fentanyl after naloxone for uremic pruritus.
Finsterer
Josef
J
Keller
Hans
H
Arias
Ingrid
I
Zuntner
Günter
G
D000279:Administration, Cutaneous; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000009:adverse effects; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005283:Fentanyl / Q000008:administration & dosage* / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009270:Naloxone / Q000009:adverse effects* / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000008:administration & dosage / Q000009:adverse effects; D010146:Pain / Q000188:drug therapy* / Q000517:prevention & control; D011537:Pruritus / Q000188:drug therapy*; D013375:Substance Withdrawal Syndrome / Q000209:etiology*; D014511:Uremia / Q000188:drug therapy; D028761:Withholding Treatment
D000701:Analgesics, Opioid; D009292:Narcotic Antagonists; D009270:Naloxone; D005283:Fentanyl